Darapladib - CISMeF

Preferred Label : Darapladib;

NCIt definition : A substituted pyrimidone with inhibitory activity towards lipoprotein-associated phospholipase-A2 (Lp-PLA2), an important regulator of lipid metabolism and inflammation that circulates with lipoprotein particles and is carried into the arterial wall with low-density lipoprotein particles during the progression of atherosclerosis.;

UNII : UI1U1MYH09;

InChIKey : WDPFJWLDPVQCAJ-UHFFFAOYSA-N;

CAS number : 356057-34-6;

Molecule name : SB 480848; GSK480848;

Chemical formula : C36H38F4N4O2S;

Détails

Origin ID

C72985;

UMLS CUI

C2348075;

Currated CISMeF NLP mapping
- darapladib [MeSH concept]
- darapladib [MeSH Supplementary Concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- darapladib [MeSH Supplementary Concept]
- darapladib [MeSH concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients